• Zai Lab received FDA orphan drug designation for zocilurtatug pelitecan, a DLL3-targeting ADC, in neuroendocrine carcinomas.
• The designation supports development in an area with no approved targeted therapies for previously treated patients.
• Zocilurtatug pelitecan previously received FDA fast track status for extrapulmonary NECs, plus fast track and orphan status in small cell lung cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608030700BIZWIRE_USPR_____20260803_BW575802) on August 03, 2026, and is solely responsible for the information contained therein.